22nd March 2023
Johnson & Johnson Covid-19 Janssen vaccine
Barcelona News Catalonia News Madrid News Main News

EU Medicines Agency: the Janssen vaccine benefits outweigh blood clot risks

Latest: Coronavirus in Spain figures (26 Apr)

Experts at the European Medicines Agency (EMA) have said that they have found a ‘possible link’ between Johnson & Johnson’s Janssen vaccine against Covid-19 and very rare blood clots, after a small number of cases were reported in the USA – but they have also confirmed that the vaccine’s benefits still outweigh the very small risks of recipients developing the clots.

The EMA has said a warning about the rare blood clots should be added to labels for the one-dose Janssen vaccine but that they should be considered as ‘very rare side effects’.

Spain had prioritised giving citizens aged between 7079 jabs of the Janssen vaccine – but last week the Johnson & Johnson pharmaceutical group temporarily delayed their rollout of the vaccine in Europe, following the USA regulators’ recommendation to pause its use because of possible links to rare blood clots. 

US officials had recommended a pause in the vaccine after they detected six very rare blood clot cases among nearly 7 million people who had been vaccinated (up to 13 April).

Johnson & Johnson Covid-19 Janssen vaccine
The Johnson & Johnson Covid-19 Janssen vaccine, the fourth in the EU. The vaccine requires one dose only. (Library image).

In reaching its conclusions on Tuesday that the benefits of the vaccine outweigh the risks, the EMA said that it had taken into consideration ‘all currently available evidence including eight reports from the USA of serious cases of unusual blood clots associated with low levels of blood platelets, one of which had a fatal outcome’. 

‘All cases occurred in people under 60 years of age within three weeks after vaccination, the majority in women,’ the EMA said. It went on to add that ‘the cases reviewed were very similar to the cases that occurred with the Covid-19 vaccine developed by AstraZeneca‘.

‘The benefits of the vaccine continue to outweigh the risks for people who receive it,’ the EMA concluded. ‘The vaccine is effective at preventing Covid-19 and reducing hospitalisations and deaths.’

You can click here to read the EMA’s full conclusions regarding the Janssen vaccine.

ALSO READ: Spain starts trial of giving 2nd jab of Pfizer to those who have had AstraZeneca

ALSO READ: EMA on AstraZeneca: ‘possible link to very rare cases of unusual blood clots’

Sign up for the FREE Weekly Newsletter from Spain in English.

Please support Spain in English with a donation.

Click here to get your business activity or services listed on our DIRECTORY.

Click here for further details on how to ADVERTISE with us.

Recent Posts

Spain’s government faces no-confidence vote brought by far-right Vox group

News Desk

Supreme Court maintains misuse of funds & disobedience charges against Puigdemont

News Desk

Guardia Civil find remains in Pyrenees, ‘possibly of French murder suspect’

News Desk

Activists demand EU stops ‘green’ funds used to link ski resorts in Aragón Pyrenees

News Desk

Vilanova i la Geltrú to be host venue for 1st preliminary regatta of America’s Cup

News Desk

Spanish government and unions hail ‘historic’ pension reform

News Desk

Leave a Comment